Non-Small-Cell Lung Cancer (NSCLC) Clinical Trial
Official title:
An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
The purpose of this study is to assess the safety and tolerability of ASP8273 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). This study will also determine the pharmacokinetics (PK) of ASP8273, evaluate the potential inhibition of CYP3A4 by ASP8273 and the antitumor activity of ASP8273 as well as determine the effect of food on the bioavailability of ASP8273.
This study is composed of 2 parts: part 1 is the dose escalation phase and part 2 is the recommended Phase 2 dose (RP2D) phase, Food Effect (FE) cohort and Exon 20 cohort. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03725475 -
A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients
|
||
| Completed |
NCT01874678 -
A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer
|
N/A | |
| Recruiting |
NCT06357598 -
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer
|
Phase 4 | |
| Recruiting |
NCT02448992 -
Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04338620 -
Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC
|
Phase 2 | |
| Completed |
NCT06232967 -
PPIO-006 Primary Tumor Resection for IVa NSCLC
|